Neuroprotection in Parkinson's disease: An elusive goal

被引:22
作者
Biglan, Kevin M. [1 ]
Ravina, Bernard [1 ]
机构
[1] Univ Rochester, Dept Neurol, Sch Med & Dent, Rochester, NY 14620 USA
关键词
neuroprotection; clinical trials; Parkinson's disease;
D O I
10.1055/s-2007-971168
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Despite increases in our understanding of the pathophysiology and environmental and genetic influences of illness in Parkinson's disease, neuroprotection remains an elusive goal. No interventions are widely accepted as disease modifying in Parkinson's disease. Continued research identifying novel therapeutic targets is likely to result in several putative neuroprotective agents. Assimilating lessons from previous neuroprotection trials will be critical in developing future trials aimed at efficiently identifying neuroprotective treatments. Ultimately, overcoming the unique challenges of a heterogenous, slowly progressive disorder with multiple potential outcome measures will be necessary to identify treatments that have meaningful effects.
引用
收藏
页码:106 / 112
页数:7
相关论文
共 47 条
[1]
The rate of cognitive decline in Parkinson disease [J].
Aarsland, D ;
Andersen, K ;
Larsen, JP ;
Perry, R ;
Wentzel-Larsen, T ;
Lolk, A ;
Kragh-Sorensen, P .
ARCHIVES OF NEUROLOGY, 2004, 61 (12) :1906-1911
[2]
Range of neuropsychiatric disturbances in patients with Parkinson's disease [J].
Aarsland, D ;
Larsen, JP ;
Lim, NG ;
Janvin, C ;
Karlsen, K ;
Tandberg, E ;
Cummings, JL .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 67 (04) :492-496
[3]
Expanding insights of mitochondrial dysfunction in Parkinson's disease [J].
Abou-Sleiman, PM ;
Muqit, MMK ;
Wood, NW .
NATURE REVIEWS NEUROSCIENCE, 2006, 7 (03) :207-219
[4]
[Anonymous], 1996, Ann Neurol, V40, P99
[5]
[Anonymous], 2006, NEUROLOGY, DOI DOI 10.1212/01.WNL.0000234884.42413.BC
[6]
Surrogate endpoints in Parkinson's disease research [J].
Kevin M. Biglan ;
Robert G. Holloway .
Current Neurology and Neuroscience Reports, 2003, 3 (4) :314-320
[7]
BIRKMAYER W, 1961, Wien Klin Wochenschr, V73, P787
[8]
Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP [J].
Dauer, W ;
Kholodilov, N ;
Vila, M ;
Trillat, AC ;
Goodchild, R ;
Larsen, KE ;
Staal, R ;
Tieu, K ;
Schmitz, Y ;
Yuan, CA ;
Rocha, M ;
Jackson-Lewis, V ;
Hersch, S ;
Sulzer, D ;
Przedborski, S ;
Burke, R ;
Hen, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (22) :14524-14529
[9]
Fahn S, 2004, NEW ENGL J MED, V351, P2498
[10]
FAHN S, 1992, SCI BASIS TREATMENT, P89